Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Beeline Holdings, Inc.EAST · Entity 7378 | Director | June 30, 2019 | July 02, 2019 |
| Cadrenal Therapeutics, Inc.CVKD · Entity 8251 | Chief Financial Officer | December 29, 2025 | December 31, 2025 |
| INVO Fertility, Inc.IVF · Entity 8473 | Director | December 03, 2025 | December 06, 2025 |
| S&W Seed CoSANW · Entity 81242 | EVP Finance & Admin and CFO | October 05, 2021 | October 07, 2021 |
| SenesTech, Inc.SNES · Entity 8221 | Director | June 15, 2026 | June 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Beeline Holdings, Inc.
Report date June 30, 2019 · Filed July 02, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,179 |
Ending reported balance
After 2019-07-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2019-06-30 · Exercise / conversion · Acquired 1,112 · Balance 2,783 F1: The closing price of Eastside Distilling, Inc. on June 28, 2019 (the last trading day before the June 30, 2019 vesting date) was $4.50. The number of shares issued was based on that closing price. Row 2 · 2019-07-01 · Exercise / conversion · Acquired 4,396 · Balance 7,179 F2: The closing price of EAST on July 1, 2019 was $4.55. The number of shares issued was based on that closing price. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2019-09-30 | Direct | Not disclosed |
Reported balance
After 2019-06-30 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-06-30 · Exercise / conversion · Disposed Not disclosed · Balance Not disclosed F3: Each restricted stock unit ("RSU") is the economic equivalent of one share of Eastside Distilling, Inc. common stock. F4: On October 15, 2018, the Reporting Person was awarded $20,000 of RSUs, which vest if four quarterly installments that began on December 31, 2018 and continue thereafter on the last day of each quarter through and including September 30, 2019, subject to continued service with the Issuer on each respective vesting date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2019-07-01 | Direct | Not disclosed |
Reported balance
After 2019-07-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-07-01 · Grant · Acquired Not disclosed · Balance Not disclosed F3: Each restricted stock unit ("RSU") is the economic equivalent of one share of Eastside Distilling, Inc. common stock. F5: On July 1, 2019, the Reporting Person was awarded $20,000 of RSUs, all of which vested immediately. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2019-07-01 | Direct | Not disclosed |
Reported balance
After 2019-07-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-07-01 · Exercise / conversion · Disposed Not disclosed · Balance Not disclosed F3: Each restricted stock unit ("RSU") is the economic equivalent of one share of Eastside Distilling, Inc. common stock. F5: On July 1, 2019, the Reporting Person was awarded $20,000 of RSUs, all of which vested immediately. |
Filing footnotes · ownership attribution and instrument terms
F1: The closing price of Eastside Distilling, Inc. on June 28, 2019 (the last trading day before the June 30, 2019 vesting date) was $4.50. The number of shares issued was based on that closing price.
F2: The closing price of EAST on July 1, 2019 was $4.55. The number of shares issued was based on that closing price.
F3: Each restricted stock unit ("RSU") is the economic equivalent of one share of Eastside Distilling, Inc. common stock.
F4: On October 15, 2018, the Reporting Person was awarded $20,000 of RSUs, which vest if four quarterly installments that began on December 31, 2018 and continue thereafter on the last day of each quarter through and including September 30, 2019, subject to continued service with the Issuer on each respective vesting date.
F5: On July 1, 2019, the Reporting Person was awarded $20,000 of RSUs, all of which vested immediately.
Cadrenal Therapeutics, Inc.
Report date December 29, 2025 · Filed December 31, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-12-29 transaction · row 1
1 source rowRow 1 · 2025-12-29 · Sale · Disposed 9,933 · Balance 0 F1: Represents shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement adopted by the Reporting Person on September 18, 2025, in multiple transactions at prices ranging from $6.83 through $7.37, inclusive, having a weighted average price as shown in column 4 of $6.97. The Reporting Person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement adopted by the Reporting Person on September 18, 2025, in multiple transactions at prices ranging from $6.83 through $7.37, inclusive, having a weighted average price as shown in column 4 of $6.97. The Reporting Person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
INVO Fertility, Inc.
Report date December 03, 2025 · Filed December 06, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2025-12-04 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-12-03 · Sale · Disposed 4 · Balance 3 Row 2 · 2025-12-04 · Other · Disposed 3 · Balance 0 F1: The Reporting Person surrendered the shares of Common Stock to the Issuer without receiving any payment or other value in return. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.08 · Expires 2035-08-26 | Direct | 5,646 |
Reported balance
Holding disclosure · report date 2025-12-03 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 5,646 F2: As adjusted for a 1 for 8 reverse split that occurred on November 28, 2025. F3: The option vests in four equal installments beginning on the first day of the calendar quarter following August 26, 2025 and on the first day of each calendar quarter thereafter until fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person surrendered the shares of Common Stock to the Issuer without receiving any payment or other value in return.
F2: As adjusted for a 1 for 8 reverse split that occurred on November 28, 2025.
F3: The option vests in four equal installments beginning on the first day of the calendar quarter following August 26, 2025 and on the first day of each calendar quarter thereafter until fully vested.
S&W Seed Co
Report date October 05, 2021 · Filed October 07, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 138,140 |
Reported balance
After 2021-10-05 transaction · row 1
1 source rowRow 1 · 2021-10-05 · Grant · Acquired 7,490 · Balance 138,140 F1: Represents restricted stock unit award that vests in 12 quarterly installments over three years, commencing on January 1, 2022 and continuing thereafter on the first day of each succeeding fiscal quarter through and including October 1, 2024, subject to continued service with the Issuer on each respective vesting date. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.64 · Expires 2031-10-04 | Direct | 80,000 |
Reported balance
After 2021-10-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-10-05 · Grant · Acquired 80,000 · Balance 80,000 F2: The options vest in 12 quarterly installments over three years, commencing on January 1, 2022 and continuing thereafter on the first day of each succeeding fiscal quarter through and including October 1, 2024, subject to continued service with the Issuer on each respective vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock unit award that vests in 12 quarterly installments over three years, commencing on January 1, 2022 and continuing thereafter on the first day of each succeeding fiscal quarter through and including October 1, 2024, subject to continued service with the Issuer on each respective vesting date.
F2: The options vest in 12 quarterly installments over three years, commencing on January 1, 2022 and continuing thereafter on the first day of each succeeding fiscal quarter through and including October 1, 2024, subject to continued service with the Issuer on each respective vesting date.
SenesTech, Inc.
Report date June 15, 2026 · Filed June 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.65 · Expires 2036-06-15 | Direct | 100,000 |
Reported balance
After 2026-06-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-15 · Grant · Acquired 100,000 · Balance 100,000 F1: Monthly over 1 year (12 equal monthly installments) |
Filing footnotes · ownership attribution and instrument terms
F1: Monthly over 1 year (12 equal monthly installments)
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 15, 2026 Filed Jun 17, 2026 20:20 UTC | SenesTech, Inc. SNES · Entity 8221 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $1.65 | $0.00 |
DisclosureSEC source: 0001628280-26-043912 · wk-form4_1781727634.xml · derivative · entry 1 Szot Matthew K · CIK 0001401385 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2036-06-15 F1 · derivative.exercise_date: Monthly over 1 year (12 equal monthly installments) Read SEC document |
| December 29, 2025 Filed Dec 31, 2025 21:05 UTC | Cadrenal Therapeutics, Inc. CVKD · Entity 8251 | SaleCommon Stock | 9,933 | $6.97 | $69,233.01 |
DisclosureSEC source: 0001213900-25-127110 · ownership.xml · nonDerivative · entry 1 Szot Matthew K · CIK 0001401385 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · price: Represents shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement adopted by the Reporting Person on September 18, 2025, in multiple transactions at prices ranging from $6.83 through $7.37, inclusive, having a weighted average price as shown in column 4 of $6.97. The Reporting Person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 04, 2025 Filed Dec 6, 2025 02:40 UTC | INVO Fertility, Inc. IVF · Entity 8473 | OtherCommon stock | 3 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-25-026483 · ownership.xml · nonDerivative · entry 2 Szot Matthew K · CIK 0001401385 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: The Reporting Person surrendered the shares of Common Stock to the Issuer without receiving any payment or other value in return. Read SEC document |
| December 03, 2025 Filed Dec 6, 2025 02:40 UTC | INVO Fertility, Inc. IVF · Entity 8473 | SaleCommon stock | 4 | $1.52 | $6.08 |
DisclosureSEC source: 0001493152-25-026483 · ownership.xml · nonDerivative · entry 1 Szot Matthew K · CIK 0001401385 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3 Read SEC document |
| November 14, 2025 Filed Nov 17, 2025 20:00 UTC | SenesTech, Inc. SNES · Entity 8221 | SaleCommon Stock | 1 | $2.75 | $2.75 |
DisclosureSEC source: 0001628280-25-052557 · wk-form4_1763409609.xml · nonDerivative · entry 1 Szot Matthew K · CIK 0001401385 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Read SEC document |
| October 27, 2025 Filed Oct 28, 2025 21:00 UTC | Cadrenal Therapeutics, Inc. CVKD · Entity 8251 | SaleCommon Stock | 1,800 | $13.99 | $25,182.00 |
DisclosureSEC source: 0001213900-25-103147 · ownership.xml · nonDerivative · entry 2 Szot Matthew K · CIK 0001401385 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,933 F1 · price: Represents shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement adopted by the Reporting Person on May 9, 2025. Read SEC document |
| October 24, 2025 Filed Oct 28, 2025 21:00 UTC | Cadrenal Therapeutics, Inc. CVKD · Entity 8251 | SaleCommon Stock | 1,800 | $13.99 | $25,182.00 |
DisclosureSEC source: 0001213900-25-103147 · ownership.xml · nonDerivative · entry 1 Szot Matthew K · CIK 0001401385 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,733 F1 · price: Represents shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement adopted by the Reporting Person on May 9, 2025. Read SEC document |
| October 13, 2025 Filed Oct 14, 2025 20:05 UTC | Cadrenal Therapeutics, Inc. CVKD · Entity 8251 | SaleCommon Stock | 1,800 | $14.07 | $25,326.00 |
DisclosureSEC source: 0001213900-25-098718 · ownership.xml · nonDerivative · entry 2 Szot Matthew K · CIK 0001401385 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,533 F1 · price: Represents shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement. Read SEC document |
| October 09, 2025 Filed Oct 14, 2025 20:05 UTC | Cadrenal Therapeutics, Inc. CVKD · Entity 8251 | SaleCommon Stock | 1,693 | $13.99 | $23,685.07 |
DisclosureSEC source: 0001213900-25-098718 · ownership.xml · nonDerivative · entry 1 Szot Matthew K · CIK 0001401385 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,333 F1 · price: Represents shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement. Read SEC document |
| October 06, 2025 Filed Oct 8, 2025 00:22 UTC | Cadrenal Therapeutics, Inc. CVKD · Entity 8251 | SaleCommon Stock | 107 | $13.99 | $1,496.93 |
DisclosureSEC source: 0001213900-25-097178 · ownership.xml · nonDerivative · entry 1 Szot Matthew K · CIK 0001401385 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,026 F1 · price: Represents shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement. Read SEC document |
| October 01, 2025 Filed Oct 1, 2025 21:47 UTC | Cadrenal Therapeutics, Inc. CVKD · Entity 8251 | SaleCommon Stock | 1,700 | $13.99 | $23,783.00 |
DisclosureSEC source: 0001213900-25-094804 · ownership.xml · nonDerivative · entry 2 Szot Matthew K · CIK 0001401385 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,133 F2 · price: Represents shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement in multiple transactions at prices ranging from $13.99 through $14.00, inclusive, having a weighted average price as shown in column 4 of $13.99. The Reporting Person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 29, 2025 Filed Oct 1, 2025 21:47 UTC | Cadrenal Therapeutics, Inc. CVKD · Entity 8251 | SaleCommon Stock | 100 | $14.00 | $1,400.00 |
DisclosureSEC source: 0001213900-25-094804 · ownership.xml · nonDerivative · entry 1 Szot Matthew K · CIK 0001401385 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,833 F1 · price: Represents shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement. Read SEC document |
| September 25, 2025 Filed Sep 27, 2025 00:36 UTC | Cadrenal Therapeutics, Inc. CVKD · Entity 8251 | SaleCommon Stock | 10,900 | $14.05 | $153,182.06 |
DisclosureSEC source: 0001213900-25-092558 · ownership.xml · nonDerivative · entry 2 Szot Matthew K · CIK 0001401385 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,933 F2 · price: Represents shares of the Issuer's common stock sold by the Reporting Person in multiple transactions at prices ranging from $13.99 through $14.52, inclusive, having a weighted average price as shown in column 4 of $14.0534. The Reporting Person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 24, 2025 Filed Sep 27, 2025 00:36 UTC | Cadrenal Therapeutics, Inc. CVKD · Entity 8251 | SaleCommon Stock | 1,500 | $14.00 | $20,992.95 |
DisclosureSEC source: 0001213900-25-092558 · ownership.xml · nonDerivative · entry 1 Szot Matthew K · CIK 0001401385 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,833 F1 · price: Represents shares of the Issuer's common stock sold by the Reporting Person in multiple transactions at prices ranging from $13.99 through $14.02, inclusive, having a weighted average price as shown in column 4 of $13.9953. The Reporting Person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 28, 2025 Filed Aug 30, 2025 00:35 UTC | Cadrenal Therapeutics, Inc. CVKD · Entity 8251 | SaleCommon Stock | 400 | $14.00 | $5,600.00 |
DisclosureSEC source: 0001213900-25-082821 · ownership.xml · nonDerivative · entry 2 Szot Matthew K · CIK 0001401385 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,333 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions, each at $14.000. The reporting person undertakes to provide to Cadrenal Therapeutics, Inc., any security holder of Cadrenal Therapeutics, Inc. or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 27, 2025 Filed Aug 30, 2025 00:35 UTC | Cadrenal Therapeutics, Inc. CVKD · Entity 8251 | SaleCommon Stock | 1,600 | $14.00 | $22,392.00 |
DisclosureSEC source: 0001213900-25-082821 · ownership.xml · nonDerivative · entry 1 Szot Matthew K · CIK 0001401385 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,733 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.99 through $14.00. The reporting person undertakes to provide to Cadrenal Therapeutics, Inc., any security holder of Cadrenal Therapeutics, Inc. or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 26, 2025 Filed Aug 29, 2025 01:18 UTC | INVO Fertility, Inc. IVF · Entity 8473 | GrantStock Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $1.01 | $0.00 |
DisclosureSEC source: 0001641172-25-025869 · ownership.xml · derivative · entry 2 Szot Matthew K · CIK 0001401385 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,164 Underlying: Common Stock · 45,000 shares Expires 2035-08-26 F1 · derivative.exercise_date: The option vests in four equal installments beginning on the first day of the calendar quarter following August 26, 2025 and on the first day of each calendar quarter thereafter until fully vested. Read SEC document |
| January 23, 2025 Filed Jan 24, 2025 23:10 UTC | Cadrenal Therapeutics, Inc. CVKD · Entity 8251 | GrantStock Options · Derivative | 50,000 | $0.00 Strike: $19.79 | $0.00 |
DisclosureSEC source: 0001213900-25-006633 · ownership.xml · derivative · entry 1 Szot Matthew K · CIK 0001401385 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2035-01-22 F1 · security: Consists of options to purchase 50,000 shares of common stock, which shall vest 1/4 on February 1, 2026 and thereafter pro rata on a monthly basis over three years, subject to the Reporting Person's continued service to the Issuer through each vesting date, having an exercise price equal to the fair market value of the Issuer's common stock on the effective date of the grant. Read SEC document |
| August 27, 2024 Filed Aug 28, 2024 21:12 UTC | SenesTech, Inc. SNES · Entity 8221 | GrantStock Option (right to buy) · Derivative | 12,090 | $0.00 Strike: $2.81 | $0.00 |
DisclosureSEC source: 0001628280-24-038706 · wk-form4_1724879550.xml · derivative · entry 1 Szot Matthew K · CIK 0001401385 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,090 Underlying: Common Stock · 12,090 shares Expires 2034-08-27 F1 · derivative.exercise_date: The option will vest and become exercisable as to 25% of the total shares on November 27, 2024, February 27, 2025, May 27, 2025 and August 27, 2025, with 100% of the options fully vested on the earlier of the first anniversary of the date of grant or the first annual meeting of stockholders of the Corporation after the date of grant (subject to the recipient's continued service to the Corporation through such vesting date). Read SEC document |
| January 18, 2024 Filed Jan 20, 2024 00:39 UTC | Cadrenal Therapeutics, Inc. CVKD · Entity 8251 | GrantStock Options · Derivative | 250,000 | $0.00 Strike: $0.94 | $0.00 |
DisclosureSEC source: 0001213900-24-004999 · ownership.xml · derivative · entry 1 Szot Matthew K · CIK 0001401385 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2034-01-17 F1 · security: These options vest 25% on February 1, 2025 and thereafter pro rata on a monthly basis for the next 36 months. F1 · derivative.exercise_date: These options vest 25% on February 1, 2025 and thereafter pro rata on a monthly basis for the next 36 months. Read SEC document |
| June 26, 2023 Filed Jun 29, 2023 22:41 UTC | SenesTech, Inc. SNES · Entity 8221 | GrantStock Option (right to buy) · Derivative | 39,402 | $0.00 Strike: $1.25 | $0.00 |
DisclosureSEC source: 0001628280-23-023951 · wk-form4_1688078493.xml · derivative · entry 1 Szot Matthew K · CIK 0001401385 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,402 Underlying: Common Stock · 39,402 shares Expires 2028-06-26 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total shares on September 26, 2023, December 26, 2023, March 26, 2024 and June 26, 2024, with 100% of the options fully vested on the earlier of the first anniversary of the grant date or the first annual meeting of stockholders of the Company after the grant date (subject to the recipient's continued service to the Company through such vesting date). Read SEC document |
| May 18, 2023 Filed May 23, 2023 00:13 UTC | INVO Fertility, Inc. INVO · Entity 8473 | GrantStock Option (right to buy) · Derivative | 85,000 | $0.00 Strike: $0.37 | $0.00 |
DisclosureSEC source: 0001493152-23-018630 · ownership.xml · derivative · entry 1 Szot Matthew K · CIK 0001401385 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,000 Underlying: Common Stock · 85,000 shares Expires 2033-05-17 F1 · derivative.exercise_date: The option vests in four equal installments beginning on May 17, 2023 and on each calendar quarter-end thereafter until fully vested. Read SEC document |
| January 24, 2023 Filed Jan 24, 2023 22:01 UTC | Cadrenal Therapeutics, Inc. CVKD · Entity 8251 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-23-004883 · ownership.xml · nonDerivative · entry 1 Szot Matthew K · CIK 0001401385 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Read SEC document |
| July 01, 2022 Filed Jul 6, 2022 22:18 UTC | SenesTech, Inc. SNES · Entity 8221 | GrantStock Option (right to buy) · Derivative | 209,025 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0001209191-22-041332 · doc4.xml · derivative · entry 1 Szot Matthew K · CIK 0001401385 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,025 Underlying: Common Stock · 209,025 shares Expires 2027-07-01 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total shares on the first day of each calendar quarter following the date of grant, with 100% of the options fully vested on the earlier of the first anniversary of the grant date or the first annual meeting of stockholders of the Company after the grant date (subject to the recipient's continued service to the Company through such vesting date). Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 22:45 UTC | INVO Fertility, Inc. INVO · Entity 8473 | PurchaseCommon Stock | 14,474 | $0.95 | $13,750.30 |
DisclosureSEC source: 0001493152-22-015909 · ownership.xml · nonDerivative · entry 1 Szot Matthew K · CIK 0001401385 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,175 Read SEC document |
| January 15, 2022 Filed Jan 19, 2022 02:27 UTC | INVO Fertility, Inc. INVO · Entity 8473 | GrantStock Option · Derivative | 12,454 | $0.00 Strike: $3.61 | $0.00 |
DisclosureSEC source: 0001493152-22-001531 · ownership.xml · derivative · entry 2 Szot Matthew K · CIK 0001401385 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,454 Underlying: Common Stock · 12,454 shares Expires 2032-01-14 F1 · derivative.exercise_date: The stock option vests in monthly increments over a period of twelve months from the date of grant. Read SEC document |
| January 15, 2022 Filed Jan 19, 2022 02:27 UTC | INVO Fertility, Inc. INVO · Entity 8473 | GrantCommon Stock | 10,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-22-001531 · ownership.xml · nonDerivative · entry 1 Szot Matthew K · CIK 0001401385 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,701 Read SEC document |
| October 05, 2021 Filed Oct 7, 2021 17:39 UTC | S&W Seed Co SANW · Entity 81242 | GrantStock option (right to buy) · Derivative | 80,000 | $0.00 Strike: $2.64 | $0.00 |
DisclosureSEC source: 0001209191-21-059957 · doc4.xml · derivative · entry 2 Szot Matthew K · CIK 0001401385 · EVP Finance & Admin and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2031-10-04 F2 · derivative.exercise_date: The options vest in 12 quarterly installments over three years, commencing on January 1, 2022 and continuing thereafter on the first day of each succeeding fiscal quarter through and including October 1, 2024, subject to continued service with the Issuer on each respective vesting date. Read SEC document |
| October 05, 2021 Filed Oct 7, 2021 17:39 UTC | S&W Seed Co SANW · Entity 81242 | GrantCommon Stock | 7,490 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-059957 · doc4.xml · nonDerivative · entry 1 Szot Matthew K · CIK 0001401385 · EVP Finance & Admin and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,140 F1 · shares: Represents restricted stock unit award that vests in 12 quarterly installments over three years, commencing on January 1, 2022 and continuing thereafter on the first day of each succeeding fiscal quarter through and including October 1, 2024, subject to continued service with the Issuer on each respective vesting date. Read SEC document |
| October 01, 2021 Filed Oct 4, 2021 17:03 UTC | S&W Seed Co SANW · Entity 81242 | Tax withholdingCommon Stock | 1,496 | $2.56 | $3,829.76 |
DisclosureSEC source: 0001209191-21-059050 · doc4.xml · nonDerivative · entry 1 Szot Matthew K · CIK 0001401385 · EVP Finance & Admin and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,650 F1 · kind: The reporting person is reporting the withholding by the Issuer of an aggregate of 1,496 shares of common stock that vested on October 1, 2021 pursuant to RSU awards granted on October 14, 2019 and October 1, 2020, but that were not issued in order to satisfy the reporting person's tax withholding obligations upon settlement of the RSU award. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 16:24 UTC | S&W Seed Co SANW · Entity 81242 | Exercise / conversionRestricted Stock Units · Derivative | 1,040 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-045457 · doc4.xml · derivative · entry 3 Szot Matthew K · CIK 0001401385 · EVP Finance & Admin and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,040 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU is the economic equivalent of one share of S&W Seed Company common stock. The closing price of SANW on July 1, 2021 was $3.63. F4 · derivative.exercise_date: On August 31, 2018, the reporting person was granted 12,469 RSUs, of which the remaining 1,040 shares vested on July 1, 2021. The RSU vested quarterly over three years on the first day of each fiscal quarter, commencing on October 1, 2018 and continuing thereafter on the first day of each succeeding fiscal quarter through and including July 1, 2021. F4 · derivative.expiration_date: On August 31, 2018, the reporting person was granted 12,469 RSUs, of which the remaining 1,040 shares vested on July 1, 2021. The RSU vested quarterly over three years on the first day of each fiscal quarter, commencing on October 1, 2018 and continuing thereafter on the first day of each succeeding fiscal quarter through and including July 1, 2021. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 16:24 UTC | S&W Seed Co SANW · Entity 81242 | Tax withholdingCommon Stock | 1,841 | $3.63 | $6,682.83 |
DisclosureSEC source: 0001209191-21-045457 · doc4.xml · nonDerivative · entry 2 Szot Matthew K · CIK 0001401385 · EVP Finance & Admin and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,146 F3 · kind: The reporting person is reporting the withholding by the Issuer of an aggregate of 1,841 shares of common stock that vested on July 1, 2021 pursuant to RSU awards granted on August 31, 2018, October 14, 2019 and October 1, 2020, but that were not issued in order to satisfy the reporting person's tax withholding obligations upon settlement of the RSU award. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 16:24 UTC | S&W Seed Co SANW · Entity 81242 | Exercise / conversionCommon Stock | 1,040 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-045457 · doc4.xml · nonDerivative · entry 1 Szot Matthew K · CIK 0001401385 · EVP Finance & Admin and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,987 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the settlement of restricted stock units ("RSUs") that vested on July 1, 2021 through the issuance of shares of common stock. F2 · price: Each RSU is the economic equivalent of one share of S&W Seed Company common stock. The closing price of SANW on July 1, 2021 was $3.63. Read SEC document |
| June 25, 2021 Filed Jun 29, 2021 22:25 UTC | SenesTech, Inc. SNES · Entity 8221 | GrantStock Option (right to buy) · Derivative | 66,470 | $0.00 Strike: $1.66 | $0.00 |
DisclosureSEC source: 0001225208-21-009705 · doc4.xml · derivative · entry 1 Szot Matthew K · CIK 0001401385 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,470 Underlying: Common Stock · 66,470 shares Expires 2026-06-25 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total shares on the first day of each calendar quarter following the date of grant, with 100% of the options fully vested on earlier of the first anniversary of the grant date or the first annual meeting of stockholders of the Company after the grant date (subject to the recipient's continued service to the Company through such vesting date). Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 16:58 UTC | S&W Seed Co SANW · Entity 81242 | Exercise / conversionRestricted Stock Units · Derivative | 1,039 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-025191 · doc4.xml · derivative · entry 3 Szot Matthew K · CIK 0001401385 · EVP Finance & Admin and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,040 Underlying: Common Stock · 1,039 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU is the economic equivalent of one share of S&W Seed Company common stock. The closing price of SANW on April 1, 2021 was $3.72. F4 · derivative.exercise_date: On August 31, 2018, the reporting person was granted 12,439 RSUs, of which 1,039 vested on April 1, 2021. The remaining unvested RSUs will continue to vest in equal installments the first day of each quarter through and including July 1, 2021, subject to the reporting person's continued service with the Issuer on each respective vesting date. F4 · derivative.expiration_date: On August 31, 2018, the reporting person was granted 12,439 RSUs, of which 1,039 vested on April 1, 2021. The remaining unvested RSUs will continue to vest in equal installments the first day of each quarter through and including July 1, 2021, subject to the reporting person's continued service with the Issuer on each respective vesting date. Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 16:58 UTC | S&W Seed Co SANW · Entity 81242 | Tax withholdingCommon Stock | 2,205 | $3.72 | $8,202.60 |
DisclosureSEC source: 0001209191-21-025191 · doc4.xml · nonDerivative · entry 2 Szot Matthew K · CIK 0001401385 · EVP Finance & Admin and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,947 F2 · kind: The reporting person is reporting the withholding by the Issuer of an aggregate of 2,205 shares of common stock that vested on April 1, 2021 pursuant to RSU awards granted on August 31, 2018, October 14, 2019 and October 1, 2020, but that were not issued in order to satisfy the reporting person's tax withholding obligations upon settlement of the RSU award. Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 16:58 UTC | S&W Seed Co SANW · Entity 81242 | Exercise / conversionCommon Stock | 1,039 | $3.72 | $3,865.08 |
DisclosureSEC source: 0001209191-21-025191 · doc4.xml · nonDerivative · entry 1 Szot Matthew K · CIK 0001401385 · EVP Finance & Admin and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,152 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the settlement of restricted stock units ("RSUs") that vested on April 1, 2021 through the issuance of shares of common stock. Read SEC document |
| January 01, 2021 Filed Jan 5, 2021 16:10 UTC | S&W Seed Co SANW · Entity 81242 | Exercise / conversionRestricted Stock Units · Derivative | 1,039 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-000968 · doc4.xml · derivative · entry 3 Szot Matthew K · CIK 0001401385 · EVP Finance & Admin and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,079 Underlying: Common Stock · 1,039 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU is the economic equivalent of one share of S&W Seed Company common stock. The closing price of SANW on December 31, 2020 was $2.93. F4 · derivative.exercise_date: On August 31, 2018, the reporting person was granted 12,439 RSUs, of which 1,039 vested on January 1, 2021. The remaining unvested RSUs will continue to vest in equal installments the first day of each quarter through and including July 1, 2021, subject to the reporting person's continued service with the Issuer on each respective vesting date. F4 · derivative.expiration_date: On August 31, 2018, the reporting person was granted 12,439 RSUs, of which 1,039 vested on January 1, 2021. The remaining unvested RSUs will continue to vest in equal installments the first day of each quarter through and including July 1, 2021, subject to the reporting person's continued service with the Issuer on each respective vesting date. Read SEC document |
| January 01, 2021 Filed Jan 5, 2021 16:10 UTC | S&W Seed Co SANW · Entity 81242 | Tax withholdingCommon Stock | 2,204 | $2.93 | $6,457.72 |
DisclosureSEC source: 0001209191-21-000968 · doc4.xml · nonDerivative · entry 2 Szot Matthew K · CIK 0001401385 · EVP Finance & Admin and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,113 F2 · kind: The reporting person is reporting the withholding by the Issuer of an aggregate of 2,204 shares of common stock that vested on January 1, 2021 pursuant to RSU awards granted on August 31, 2018, October 14, 2019 and October 1, 2020, but that were not issued in order to satisfy the reporting person's tax withholding obligations upon settlement of the RSU award. Read SEC document |
| January 01, 2021 Filed Jan 5, 2021 16:10 UTC | S&W Seed Co SANW · Entity 81242 | Exercise / conversionCommon Stock | 1,039 | $2.93 | $3,044.27 |
DisclosureSEC source: 0001209191-21-000968 · doc4.xml · nonDerivative · entry 1 Szot Matthew K · CIK 0001401385 · EVP Finance & Admin and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,317 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the settlement of restricted stock units ("RSUs") that vested on January 1, 2021 through the issuance of shares of common stock. Read SEC document |
| December 31, 2020 Filed Jan 6, 2021 01:11 UTC | INVO Fertility, Inc. INVO · Entity 8473 | GrantStock Option · Derivative | 16,202 | $0.00 Strike: $3.06 | $0.00 |
DisclosureSEC source: 0001185185-21-000024 · ownership.xml · derivative · entry 2 Szot Matthew K · CIK 0001401385 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,202 Underlying: Common Stock · 16,202 shares Expires 2030-12-31 F1 · derivative.exercise_date: The restricted stock and the option vest in monthly increments over a period of twelve months from the date of grant. Read SEC document |
| December 31, 2020 Filed Jan 6, 2021 01:11 UTC | INVO Fertility, Inc. INVO · Entity 8473 | GrantRestricted Stock | 12,112 | $0.00 | $0.00 |
DisclosureSEC source: 0001185185-21-000024 · ownership.xml · nonDerivative · entry 1 Szot Matthew K · CIK 0001401385 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,451 F1 · security: The restricted stock and the option vest in monthly increments over a period of twelve months from the date of grant. Read SEC document |
| November 27, 2020 Filed Dec 1, 2020 22:32 UTC | INVO Fertility, Inc. INVO · Entity 8473 | GrantStock Option · Derivative | 2,339 | $0.00 Strike: $3.19 | $0.00 |
DisclosureSEC source: 0001185185-20-001695 · ownership.xml · derivative · entry 2 Szot Matthew K · CIK 0001401385 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,339 Underlying: Common Stock · 2,339 shares Expires 2025-11-27 Read SEC document |
| November 27, 2020 Filed Dec 1, 2020 22:32 UTC | INVO Fertility, Inc. INVO · Entity 8473 | GrantCommon Stock | 2,339 | $0.00 | $0.00 |
DisclosureSEC source: 0001185185-20-001695 · ownership.xml · nonDerivative · entry 1 Szot Matthew K · CIK 0001401385 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,339 Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 18:08 UTC | S&W Seed Co SANW · Entity 81242 | Exercise / conversionRestricted Stock Units · Derivative | 1,039 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-053850 · doc4.xml · derivative · entry 5 Szot Matthew K · CIK 0001401385 · EVP Finance & Admin and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,118 Underlying: Common Stock · 1,039 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each RSU is the economic equivalent of one share of S&W Seed Company common stock. The closing price of SANW on the October 1, 2020 vesting date was $2.41. F6 · derivative.exercise_date: On August 31, 2018, the reporting person was granted 12,439 RSUs, of which 1,039 vested on October 1, 2020. The remaining unvested RSUs will continue to vest in equal installments the first day of each quarter through and including July 1, 2021, subject to the reporting person's continued service with the Issuer on each respective vesting date. F6 · derivative.expiration_date: On August 31, 2018, the reporting person was granted 12,439 RSUs, of which 1,039 vested on October 1, 2020. The remaining unvested RSUs will continue to vest in equal installments the first day of each quarter through and including July 1, 2021, subject to the reporting person's continued service with the Issuer on each respective vesting date. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 18:08 UTC | S&W Seed Co SANW · Entity 81242 | GrantStock options (right to buy) · Derivative | 150,000 | $0.00 Strike: $2.41 | $0.00 |
DisclosureSEC source: 0001209191-20-053850 · doc4.xml · derivative · entry 4 Szot Matthew K · CIK 0001401385 · EVP Finance & Admin and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2030-10-01 F4 · derivative.exercise_date: The options vest in 12 quarterly installments over three years, commencing on January 1, 2021 and continuing thereafter on the first day of each succeeding fiscal quarter through and including October 1, 2023, subject to continued service with the Issuer on each respective vesting date. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 18:08 UTC | S&W Seed Co SANW · Entity 81242 | Tax withholdingCommon Stock | 1,397 | $2.41 | $3,366.77 |
DisclosureSEC source: 0001209191-20-053850 · doc4.xml · nonDerivative · entry 3 Szot Matthew K · CIK 0001401385 · EVP Finance & Admin and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,278 F3 · kind: The reporting person is reporting the withholding by the Issuer of an aggregate of 1,397 shares of common stock that vested on October 1, 2020 pursuant to the RSU award referred to in Table II and an RSU award granted on October 14, 2019, but that were not issued in order to satisfy the reporting person's tax withholding obligations upon settlement of the RSU award. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 18:08 UTC | S&W Seed Co SANW · Entity 81242 | Exercise / conversionCommon Stock | 1,039 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-053850 · doc4.xml · nonDerivative · entry 2 Szot Matthew K · CIK 0001401385 · EVP Finance & Admin and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,675 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Represents the settlement of restricted stock units ("RSUs") that vested on October 1, 2020 through the issuance of shares of common stock. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 18:08 UTC | S&W Seed Co SANW · Entity 81242 | GrantCommon Stock | 15,919 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-053850 · doc4.xml · nonDerivative · entry 1 Szot Matthew K · CIK 0001401385 · EVP Finance & Admin and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,636 F1 · shares: The shares being reported are being issued pursuant to restricted stock unit awards ("RSUs"), each one of which represents a contingent right to receive one share of the Issuer's common stock. 1/12th of the shares subject to the RSUs will vest on January 1, 2021, and the remainder will vest in eleven equal quarterly installments, subject to continued service with the Issuer on each respective vesting date. Read SEC document |
| July 10, 2020 Filed Jul 15, 2020 15:46 UTC | SenesTech, Inc. SNES · Entity 8221 | GrantStock Option (right to buy) · Derivative | 31,401 | $0.00 Strike: $1.97 | $0.00 |
DisclosureSEC source: 0001225208-20-009750 · doc4.xml · derivative · entry 1 Szot Matthew K · CIK 0001401385 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,401 Underlying: Common Stock · 31,401 shares Expires 2025-07-10 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total shares on the first day of each calendar quarter following the date of grant provided that any portion remaining unvested as of the one-year anniversary of the date of grant will vest as of such date (subject to recipient's continued service to the Company through such vesting dates). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.